Howard Marks Bei Gene, Ltd. Transaction History

Oaktree Capital Management LP

  • $4.72 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 13, 2019
SELL
$120.61 - $148.29 $3.22 Million - $3.96 Million
-26,700 Closed
0 $0
Q2 2019

Aug 14, 2019
BUY
$113.99 - $146.86 $3.04 Million - $3.92 Million
26,700 New
26,700 $3.31 Million

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.2B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track Howard Marks's Portfolio

Track Howard Marks Portfolio

Follow Howard Marks (Oaktree Capital Management LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oaktree Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Oaktree Capital Management LP and Howard Marks with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email